Literature DB >> 29948004

CT-Guided Microwave Ablation of Liver Tumors in Anatomically Challenging Locations.

Van Dai Vo Chieu1, Thomas Werncke1, Bennet Hensen1, Frank Wacker1, Kristina I Ringe2.   

Abstract

PURPOSE: To assess the feasibility and outcome of microwave ablation (MWA) of hepatic tumors in anatomically challenging locations.
MATERIALS AND METHODS: A total of 94 patients with 174 hepatic tumors referred for CT-guided MWA were included in this retrospective institutional review board-approved study. One hundred and twenty-five tumors (median size 17 mm, range 12-24 mm) with subcapsular location (n = 91) and/or in which a transpleural approach was applied (n = 53) were identified (group 1) and compared to tumors with a central intrahepatic location (group 2; n = 49, median size 19 mm, range 12-23 mm). Technical success, complications and local tumor progression (LTP) were evaluated. Risk factors were analyzed using univariate analysis, logistic regression and Kaplan-Meier curves (p < 0.05 deemed significant).
RESULTS: Technical success was 100% in both groups. In group 1, complications occurred in n = 31 tumors (24.8%; pneumothorax n = 20; hematoma n = 11). Complications occurred significantly less often in group 2 (8.2%; n = 4 (hematoma); p = 0.011). There were no major complications. Transpleural approach and number of capsule punctures were identified as risk factors for complications (all p < 0.05). Median follow-up was 265 days. LTP was comparable between both groups (13.6 vs. 10.2%; p = 0.41). Use of hydrodissection was the only independent factor associated with LTP (p = 0.03, HR 3.29).
CONCLUSION: CT-guided hepatic MWA of subcapsular tumors and subdiaphragmatic tumors requiring a direct or transpleural approach is feasible with increased minor but not major complications. LTP did not differ significantly between both groups.

Entities:  

Keywords:  Liver; Liver tumor; Microwave ablation; Subcapsular; Subdiaphragmatic

Mesh:

Year:  2018        PMID: 29948004     DOI: 10.1007/s00270-018-2007-z

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  6 in total

1.  Single medium-sized hepatocellular carcinoma treated with sequential conventional transarterial chemoembolization (cTACE) and microwave ablation at 4 weeks versus cTACE alone: a propensity score.

Authors:  Zi-Yi Zhu; Mu Yuan; Pei-Pei Yang; Bo Xie; Jian-Zhu Wei; Zhong-Qiang Qin; Zhen Qian; Zhao-Ying Wang; Long-Fei Fan; Jing-Yu Qian; Yu-Lin Tan
Journal:  World J Surg Oncol       Date:  2022-06-10       Impact factor: 3.253

2.  Feasibility, safety, and long-term efficacy of stereotactic radiofrequency ablation for tumors adjacent to the diaphragm in the hepatic dome: a case-control study.

Authors:  Peter Schullian; Daniel Putzer; Gregor Laimer; Elliot Levy; Reto Bale
Journal:  Eur Radiol       Date:  2019-09-05       Impact factor: 5.315

3.  Reduction of microwave ablation needle related metallic artifacts using virtual monoenergetic images from dual-layer detector spectral CT in a rabbit model with VX2 tumor.

Authors:  Guorong Wang; Qinzong Gao; Zhiwei Wang; Xiaomei Lu; Shenghui Yu; Zhengyu Jin
Journal:  Sci Rep       Date:  2021-04-29       Impact factor: 4.379

4.  CT-guided microwave ablation of hepatic malignancies via transpulmonary approach without ancillary techniques.

Authors:  Driss Raissi; Sreeja Sanampudi; Qian Yu; Michael Winkler
Journal:  J Clin Imaging Sci       Date:  2022-01-20

5.  CT-monitored minimal ablative margin control in single-session microwave ablation of liver tumors: an effective strategy for local tumor control.

Authors:  Ijin Joo; Kenneth W Morrow; Steven S Raman; Justin P McWilliams; James W Sayre; David S Lu
Journal:  Eur Radiol       Date:  2022-04-07       Impact factor: 7.034

6.  Clinical and functional results of radiofrequency ablation and microwave ablation in patients with benign thyroid nodules.

Authors:  Mirkhalig Javadov; Emrah Karatay; Mustafa U Ugurlu
Journal:  Saudi Med J       Date:  2021-08       Impact factor: 1.422

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.